Cargando…
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
Angiotensin-converting enzyme 2 (ACE2) is the binding-site and entry-point for SARS-CoV-2 in human and highly expressed in the lung. Cigarette smoking (CS) is the leading cause of pulmonary and cardiovascular diseases. Chronic CS leads to upregulation of bronchial ACE2 inducing a high vulnerability...
Autores principales: | Lugnier, Claire, Al-Kuraishy, Hayder M., Rousseau, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842152/ https://www.ncbi.nlm.nih.gov/pubmed/33515531 http://dx.doi.org/10.1016/j.bcp.2021.114431 |
Ejemplares similares
-
The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
por: Lugnier, Claire
Publicado: (2022) -
Cigarette smoke up‐regulates PDE3 and PDE4 to decrease cAMP in airway cells
por: Zuo, Haoxiao, et al.
Publicado: (2018) -
The Involvement of PDE4 in the Protective Effects of Melatonin on Cigarette-Smoke-Induced Chronic Obstructive Pulmonary Disease
por: Lim, Je-Oh, et al.
Publicado: (2021) -
p19(Arf) Exacerbates Cigarette Smoke-Induced Pulmonary Dysfunction
por: Mikawa, Ryuta, et al.
Publicado: (2020) -
NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants
por: Yougbare, Issaka, et al.
Publicado: (2020)